Last reviewed · How we verify
NCT07038083: RED-CARPET
REal-world Data of CARdiometabolic ProtEcTion
trial in Cardiometabolic Diseases in 40,000 participants. Currently enrolling.
1 January 2044
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40,000 |
| Start date | 1 January 2014 |
| Primary completion | 1 January 2044 |
| Estimated completion | 1 January 2044 |
| Sites | 1 location across China |
Conditions studied
- Cardiometabolic Diseases — all drugs for Cardiometabolic Diseases →
Sponsor
Sun Yat-sen University
Who can join
18 and older, any sex, with Cardiometabolic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07038083
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiometabolic Diseases
Currently open trials in the same condition.
- NCT07148817 — Impact of Earplugs on Mechanisms of Noise-Related Cardiovascular Disease · NA · recruiting
- NCT06593327 — NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study · NA · recruiting
- NCT06755840 — Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study · recruiting
- NCT05216042 — GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study · NA · recruiting
- NCT07205510 — Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE) · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07038083 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07038083.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing